Clinical Data Evaluating Oral REVLIMID ® Either with Rituximab or Following ... EON: Enhanced Online News (press release) BOUDRY, Switzerland--(EON: Enhanced Online News)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a ... |
